CVS Health stock holds above $93 as Q2 2026 revenue tops $106 billion

CVS Health Corp. (US1266501006) stock has been trading in the mid-$90 range in late August 2026 as investors weigh a strong Q2 2026 revenue performance of $106.1 billion and a series of earnings beats against competitive and staffing pressures in the pharmacy and health benefits businesses as of August 24, 2026.

Q2 2026 results show solid revenue growth

Recent reporting on CVS Health for Q2 2026 highlights that the company generated revenue of $106.1 billion in the quarter, representing a 7.3% increase year on year and marking a clear acceleration versus the prior-year period. This Q2 2026 overview notes that CVS Health not only grew its top line but also delivered a quarter described as exceptional compared with many healthcare peers, reflecting momentum across retail pharmacy, pharmacy benefit management, and health insurance operations.

According to the same Q2 2026 analysis, CVS Health exceeded analysts revenue expectations by 6.7%, underlining that the $106.1 billion figure was significantly higher than the consensus estimate for the period. The coverage further indicates that the company delivered an earnings per share beat versus analyst forecasts, and that its full-year earnings guidance was ahead of earlier projections, supporting the view that CVS Health is executing ahead of prior expectations during 2026.

Guidance raised and earnings beats in 2026

A detailed review of CVS Health earnings performance in 2026 notes that in each of the first three quarterly reports of the calendar year the company surpassed consensus estimates for both revenue and profitability. This earnings-focused article describes how in the first quarter of 2026 CVS reported adjusted net income of $2.57 per share compared with a consensus of $2.21, a positive difference of $0.36 per share, indicating a material upside surprise for investors.

For the second quarter of 2026, the same analysis highlights that CVS Health again outperformed expectations with adjusted net income of $2.58 per share while the analyst consensus stood at $1.83, a gap of $0.75 per share that underscored how much stronger profitability was than anticipated. The reporting also emphasizes that CVS Health raised both its revenue and earnings guidance in the first and second quarters of 2026, meaning that management increased full-year targets in two consecutive updates based on operating momentum and improved profitability in its healthcare benefits and pharmacy segments.

The article further explains that adjusted operating income in the healthcare benefits segment rose 52% year on year in the first quarter of 2026 to more than $3 billion, while in the second quarter adjusted operating income in the same segment increased 85% year on year to $2.4 billion. These figures underscore how changes in claims patterns and premium retention supported significantly higher profitability in the insurance business, and they show that the health benefits segment has been a key driver of CVS Health performance in 2026 compared with the prior year.

Stock performance and analyst consensus

Market data as of August 24, 2026 shows CVS Health shares changing hands at $93.04 during New York trading, with an intraday low of $92.54 and an opening price of $93.15 according to a late-session quote snapshot. This intraday report indicates that the stock moved little during the session and held close to this level in the evening, suggesting that investors were consolidating positions after the recent earnings updates and guidance raises.

A separate market overview focused on healthcare stocks notes that CVS Health stock has declined 10.8% since the company reported its latest quarterly results despite the strong revenue and earnings data. The same Q2 2026 sector article points out that the shares were trading at $93.12 at the time of that analysis, placing the stock modestly below recent highs even though the company outpaced analysts expectations and raised guidance, a combination that may suggest some investor caution about competitive dynamics or future margin sustainability.

From the perspective of analyst expectations, a detailed discussion of CVS Health valuation and guidance notes that the average price target compiled from analyst estimates stands at $114.59 per share, which is 22% above the most recent closing price referenced in that article. The same valuation-focused coverage explains that this spread between the consensus price target and the current share price reflects expectations for continued earnings growth and cash generation, although investors will continue to monitor how strongly the company can maintain profitability in its core segments after the recent series of guidance increases.

Business mix and healthcare benefits momentum

The 2026 earnings commentary emphasizes that CVS Health benefits from a diversified business mix that combines retail pharmacies, pharmacy benefit management, and health insurance plans, enabling the company to capture revenue at multiple stages of the healthcare value chain. The reported 52% year-on-year increase in adjusted operating income in the healthcare benefits segment in the first quarter of 2026, followed by an 85% increase in the second quarter to $2.4 billion, demonstrates how this diversification can translate into stronger profitability when claims trends and premium retention become more favorable.

In addition, recent reporting highlights that CVS Health has expanded its collaboration around weight-loss medications, including newer obesity treatments, in order to deepen its offering in pharmacy services that may generate higher prescription volumes and revenue. A current news stream notes that this focus on weight-loss drugs is intended to enhance pharmacy revenue streams at a time when competition from other retail and online pharmacies remains intense, and when staffing levels and wage costs in pharmacies continue to require careful management.

The combination of higher healthcare benefits profitability and incremental pharmacy revenue opportunities from newer treatments provides an earnings cushion, but investors remain attentive to the risk that rising utilization or regulatory changes could affect margins. The fact that CVS Health has raised its 2026 guidance twice based on recent quarters of performance underscores that management currently expects these tailwinds to outweigh potential headwinds in the near term, though the market reaction suggests that some investors are waiting for additional confirmation through future quarters.

Representative CVS Health product and services offering

Among the wide range of services CVS Health offers, one representative example is the integration of retail pharmacy locations with health insurance plans and pharmacy benefit management programs to create so-called neighborhood health destinations. In practice, this means that CVS locations serve not only as places where customers fill prescriptions but also as sites where they can access clinical services, manage chronic conditions, and coordinate benefits under health plans marketed through the company. This integrated model is central to the strategy of increasing customer engagement and capturing a larger share of healthcare spending from patients and employers.

CVS Health stock level in late August 2026

Based on late August 2026 market data, CVS Health stock most recently traded in the low-to-mid $90 range, including an intraday level of $93.04 on August 24, 2026 in New York trading, with the stock noted at $93.12 in a subsequent sector review, and an after-hours indication of $94.72 with a 1.30% gain and a further incremental move to $94.79 in the same quote stream. This quote and news overview shows that despite a 10.8% decline since the latest quarterly report, CVS Health shares are holding well above earlier 2026 lows as investors discount a combination of raised guidance, earnings outperformance, and ongoing competition in pharmacy and healthcare benefits.

Fact box

Company: CVS Health Corp.
ISIN: US1266501006
Ticker: CVS
Exchange: New York Stock Exchange
Sector / Industry: Health care / Health care providers and services
Index membership: S&P 500